{
  "docId": "019de077-72f9-7549-be02-1cb8598bb783",
  "docSlug": "e2ad68eb257d4e7a3f142ed0c8be9c7f",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 36,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Focuses on PRO (Patient Reported Outcomes) as a primary endpoint for the EBO-301 trial.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-72f9-7549-be02-1cb8598bb783/15",
  "deckHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783",
  "deckJsonHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783.json",
  "deckAnchorHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.16,
        "y": 0.56
      },
      "kind": "callout",
      "text": "EBO-301 Phase 2 is the first trial to potentially demonstrate PRO-based clinical POC in treatment-refractory MAC patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1129f485-b3b1-4399-bfaa-e6ac8f23e4e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.16,
        "y": 0.73
      },
      "kind": "callout",
      "text": "Microbial complexity in TR-MAC patient population makes sputum culture conversion difficult if not impossible to achieve; not required for approval based on FDA Guidance",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4620a09c-b14f-4a47-a29e-978dd9c5249b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.12,
        "x": 0.03,
        "y": 0.215
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b060c19b-9b14-4fb9-b1b1-55251907e3b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.16,
        "y": 0.3
      },
      "kind": "list",
      "text": "Elevating QOL-b respiratory domain, change from baseline to month 6 as the primary endpoint. Submitted statistical analysis plan to FDA (1Q25). Goal to Unblind 97 Patients enrolled in truncated Phase 3 (2Q25). Meet with FDA to review data.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7308ad17-56c7-41fb-8da2-53d234ce2bdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.16,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "PRO outcomes from Phase 2 EBO-301 trial appear aligned with FDA Guidance for primary endpoint in Phase 3 trial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d266ad07-213f-4988-b636-2f27d8a1e8c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.38,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Next: Unblind Phase 3 Data",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec3c905c-ad77-4c87-bcba-2875ef0d084c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "4aecc743-8d90-45d7-998a-91e5c70c2434",
      "evidence": "Elevating QOL-b respiratory domain, change from baseline to month 6 as the primary endpoint. Submitted statistical analysis plan to FDA (1Q25). Goal to Unblind 97 Patients enrolled in truncated Phase 3 (2Q25",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}